Ertugliflozin: A Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor for Glycemic Control in Type 2 Diabetes
Therapeutics and Clinical Risk Management
doi 10.2147/tcrm.s137068
Full Text
Open PDFAbstract
Available in full text
Date
September 1, 2018
Authors
Publisher
Informa UK Limited